Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)

Conditions

Diseases of the Nervous System | Alzheimer's Disease

Phase II-III

What is the purpose of this trial?

Brief Summary:

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

Alzheimer’s disease research Center  http://www.alzheimers.yale.edu

  • Trial with
    Biohaven Pharmaceutical Inc.
  • Start Date
    01/06/2019
  • End Date
    01/01/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Sylwia Lipior

  • Last Updated
    02/04/2019
  • Study HIC
    #2000024024